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Abstract
Background: Male breast cancer is a rare but aggressive and devastating disease. This disease
presents at a later stage and in a more advanced fashion than its female counterpart. The
immunophenotype also appears to be distinct when compared to female breast cancer.
Angiogenesis plays a permissive role in the development of a solid tumor and provides an avenue
for nutrient exchange and waste removal. Recent scrutiny of angiogenesis in female breast cancer
has shown it to be of significant prognostic value. It was hypothesized that this holds true in invasive
ductal carcinoma of the male breast. In the context of male breast cancer, we investigated the
relationship of survival and other clinico-pathological variables to the microvascular density of the
tumor tissue.
Methods: Seventy-five cases of primary male breast cancer were identified using the records of
the Saskatchewan Cancer Agency over a period of 26 years. Forty-seven cases of invasive ductal
carcinoma of the male breast had formalin-fixed paraffin-embedded tissue blocks that were suitable
for this study. All cases were reviewed. Immunohistochemical staining was performed for the
angiogenic markers (cluster designations 31 (CD31), 34 (CD34) and 105 (CD105), von Willebrand
factor (VWF), and vascular endothelial growth factor (VEGF)). Microvascular density (MVD) was
determined using average, centre, and highest microvessel counts (AMC, CMC, and HMC,
respectively). Statistical analyses compared differences in the distribution of survival times and
times to relapse between levels of MVD, tumor size, node status and age at diagnosis. In addition,
MVD values were compared within each marker, between each marker, and were also compared
to clinico-pathological data.
Results: Advanced age and tumor size were related to shorter survival times. There were no
statistically significant differences in distributions of survival times and times to relapse between
levels of MVD variables. There was no significant difference in MVD between levels of the different
clinico-pathological variables. MVD was strongly and significantly correlated between AMC, CMC
and HMC for CD31, CD34, and CD105 (p < 0.01) and remained moderate to weak for VWF and
VEGF.
Conclusion: Microvascular density does not appear to be an independent prognostic factor in
male breast cancer. However, the likelihood of death for men with breast cancer is increased in
the presence of increased age at diagnosis and advanced tumor size. This is perhaps linked to
inherent tumor vasculature, which is strongly related throughout a tumor section.
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Background
Invasive ductal carcinoma of the male breast comprises
approximately 1% of all breast cancers. Invasive ductal
carcinoma of the male breast is distinct from invasive duc-
tal carcinoma of the female breast in both presentation
and immunophenotype. Male breast cancer generally
presents in older patients and at a more advanced stage
than its female counterpart [1-3]. In contrast to female
breast cancers, ductal carcinoma in situ is quite rare in men
[4,5]. Male breast cancers are also predominantly of the
invasive ductal adenocarcinoma, not otherwise specified
(NOS) type. Invasive ductal carcinoma of the male breast,
despite being a high-grade tumor is more likely to express
estrogen receptor and/or progesterone receptor and is less
likely to over-express P53 or Erb-B2 when compared to
invasive ductal carcinoma in the female breast [6,7]. The
combination of a unique male hormonal environment, in
addition to the unique immunophenotype, points to a
distinct, non-p53-dependant, pathway of tumor progres-
sion in the male. Yet, despite these differences, it appears
that the overall prognosis for male and female breast inva-
sive ductal carcinomas are similar in age and stage-
matched studies [1,8-10].
Angiogenesis is the growth and proliferation of blood ves-
sels from existing vasculature. This process is quiescent in
normal tissues and becomes active in rapidly growing tis-
sues – including solid tumors. It has been shown that, in
order to overcome tissue death by hypoxia, tumor growth
beyond 1–2 mm3 is dependant upon the formation of
new vasculature [11]. Angiogenesis is, thus, an established
step in solid tumor progression. This has been studied in
many cancers including colorectal cancer [12] non-small
cell lung cancer [13,14], hepatocelullar cancer [15],
melanoma [16] prostate cancer [17], breast cancer [18-24]
and bladder carcinoma [25].
Most assessments of angiogenesis in female breast carci-
noma have shown it to be of significant prognostic value
[18-22]. However, not all studies in this field have
observed such important clinical correlations to MVD
[23,24]. There are a variety of techniques used to evaluate
angiogenesis and the variability between studies is proba-
bly related to the varying techniques employed in this
process.
Invasive ductal carcinoma of the male breast appears to be
a unique and biologically different carcinoma [1]; it is not
simply the appearance of female invasive ductal carci-
noma in a male breast. Due to the rarity of the disease
large cohorts are not readily available, and there is only a
limited pool of published data exploring various facets of
this important disease. In one study of 26 men with breast
cancer, elevated MVD was associated with advanced stage
of disease and poor outcome [26]. Another Japanese study
confirms that angiogenesis is part of tumor progression in
male breast cancer [27].
In an attempt to further characterize this rare tumor, the
aim of the current study was to evaluate angiogenesis in
invasive ductal carcinoma of the male breast by the assess-
ment of microvascular density in tumor samples. Specifi-
cally, we investigated three questions: (1) do survival
times and times to relapse differ between levels of MVD,
demographic, and clinico-pathological variables; (2) do
MVD measures differ between levels of demographic and
clinico-pathological variables, and finally; (3) are differ-
ent measures of MVD correlated within a section of tumor
tissue? This study is an extension of our established work
on immunophenotypic characterization of male breast
carcinoma in Saskatchewan [6].
Patients and methods
Patients
After obtaining appropriate ethics approval from the Uni-
versity of Saskatchewan Advisory Committee on Human
Experimentation, all cases (n = 75) of invasive ductal male
breast cancer diagnosed between 1975 and 1997 were
selected from the records of the Saskatchewan Cancer
Agency. Detailed chart review was performed for cases
where paraffin-embedded tissue samples were available
(n = 59). After the removal of all cases with inadequate tis-
sue sample, tissue staining and chart data, there remained
47 cases.
Clinical and pathological studies
Sections were cut from paraffin-embedded tissue samples.
The sections were stained with hematoxylin and eosin (H
& E). A detailed histopathological assessment was per-
formed. Clinical features were recorded including age at
diagnosis, date of birth, node status, tumor size, treatment
method, date of relapse, and date of death.
Age at diagnosis, tumor size, node status, disease-free sur-
vival and overall survival were the clinical variables of
interest in this study. Age at diagnosis was determined
from the patient chart. Tumor size and node status were
determined from the pathology report. Overall survival
(number of years patient survived since the diagnosis of
invasive breast carcinoma) and disease-free survival
(number of consecutive years the patient was alive with-
out breast cancer or other cancer relapse related to the
breast carcinoma since the date of diagnosis) were calcu-
lated from the information gathered in the chart review.
In cases where multiple tissue blocks were available, all H
& E sections were examined in order to select a represent-
ative tissue block with a large area of invasive tumor and
satisfactory tissue integrity.World Journal of Surgical Oncology 2005, 3:16 http://www.wjso.com/content/3/1/16
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Microvessel density determination
MVD determination was modeled after the method
described by Kato et al., [18] and Weidner et al., [28].
Immunohistochemical staining was performed for CD31,
CD34, CD105, VWF and VEGF. Staining was carried out
on a representative section by the avidin-biotin-peroxi-
dase (ABC) technique after antigen retrieval using appro-
priate positive and negative controls in all cases. The
source and dilution for each antibody are presented in
table 1.
Brown-staining areas, whether single endothelial cells or
clusters of endothelial cells, regardless of the absence/
presence of a lumen were counted as individual microves-
sels. Vessels that had a thick muscular layer were excluded
from the count. Cases were evaluated in a random order.
Two observers using a double-headed light microscope
simultaneously performed all counts for CD31, CD34,
VWF and VEGF. A single experienced observer assessed
CD105. Observers were blinded to all clinical and patho-
logical data. Average, central and highest microvessel
counts (AMC, CMC, and HMC, respectively) were
performed.
Ten high power (200×) fields along the border between
cancer nests and the stroma were evaluated for each sec-
tion (figure 1). The average number of microvessels per
high power field was determined and reported as AMC.
After scanning at low power (40×), the central area of the
tumor was estimated. From this area, six high power
(200×) fields were evaluated for each section (figure 2).
The average number of microvessels per high power field
was determined and reported as CMC. For tumors with a
central necrotic area, determination was completed using
areas near the centre of the tumor that were viable (non-
necrotic).
After scanning at low power (40×), three areas with the
highest concentration of microvessels (vascular hot spots)
were selected. Each area was evaluated with one high
power (200×) field in such a way as to include the maxi-
mum number of microvessels (figure 3). The highest
value obtained among the three fields was reported as
HMC.
Table 1: Source and dilution of antibodies used in this study
Antibody Clone Dilution Source Positive Control Negative
CD31 JC70A 1/20 Dako Human Tonsil All markers used patient tissue stained in the absence of 
primary antibody as negative control.
CD34 QBEnd10 1/20 Dako Human Tonsil
CD105 4G11 1/25 Novacastra Human Tonsil
VWF F8/36 1/40 Signet Human Tonsil
VEGF Polyclonal 1/20 Zymed Human Colon 
Cancer CEA
Average microvessel count – VEGF Figure 1
Average microvessel count – VEGF. Ten high power (200×) 
fields along the border between cancer nests and the stroma 
were evaluated for each section. The average number of 
microvessels (arrows) per high power field was determined 
and reported as AMC.World Journal of Surgical Oncology 2005, 3:16 http://www.wjso.com/content/3/1/16
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Statistical analysis
Analysis was completed using the Statistical Package for
the Social Sciences (SPSS) version 11.0 on an IBM PC
300PL computer. All tests were two tailed with the level of
statistical significance set at p < 0.05. The demographic
and clinico-pathological variables of interest included age
at diagnosis (<65 and ≥  65 years), tumor size (T1 is ≤  2
cm, T2 is >2 cm but ≤  5 cm, and T3 is >5 cm) and node
status (positive and negative).
To compare the distribution of survival times and disease
free survival times (time to relapse) we produced Kaplan-
Meier curves and made statistical comparisons using the
log-rank test between levels of demographic and clinico-
pathological variables. In addition to this we dichot-
omized the MVD variables based on the median and
repeated the Kaplan Meier with log-rank analysis to com-
pare survival times and times to relapse between levels of
MVD. For comparison of survival times, the outcome of
interest was death while the remaining subjects (those
surviving to the end of the study period) were censored.
For comparison of time to relapse, the outcome of interest
was relapse while the remaining subjects (those surviving
to the end of the study or those who died before relapse)
were censored.
Levels of MVD were also compared with levels of demo-
graphic and clinico-pathological variables using the Mann
Whitney test or Kruskal Wallis test when MVD was
considered as a continuous variable and chi squared or
Fisher's Exact test when MVD was considered as dichoto-
mous variable.
Finally, for each vascular marker (CD31, CD34, CD 105,
VWF, and VEGF), correlation between the different meas-
ures of MVD (i.e. AMC with CMC, AMC with HMC, and
CMC with HMC) was assessed using the Spearman's cor-
relation coefficient. Correlations with a coefficient (ρ ) of
≥  0.80 were considered strong, moderate-strong correla-
tions had coefficients that were <0.80 but ≥  0.50, moder-
ate-weak correlations had coefficients that were <0.50 but
≥  0.30, weak correlations had coefficients that were <0.30.
Results
Age at diagnosis and clinicopathological characteristics
In this study of 47 cases of male breast cancer, the median
age of diagnosis was 65.9 years with the youngest being 32
years and the oldest being 94 years. The frequency of male
breast cancer cases by age is illustrated in figure 4. As seen
in Table 2, most of the patients had a tumor size of T1 to
T2 and were node status negative.
Treatment regimens
All patients underwent some form of surgical resection –
most frequently a modified radical mastectomy. In 31 out
of 47 cases, surgical resection was followed by some form
of adjuvant therapy (radiotherapy, chemotherapy, hor-
Central microvessel count – VEGF Figure 2
Central microvessel count – VEGF. After scanning at low 
power (40×), the central area of the tumor was estimated. 
From this area, six high power (200×) fields were evaluated 
for each section. The average number of microvessels per 
high power field was determined and reported as CMC.
Highest microvessel count – VEGF Figure 3
Highest microvessel count – VEGF. After scanning at low 
power (40×), three areas with the highest concentration of 
microvessels (vascular hot spots) were selected. Each area 
was evaluated with one high power (200×) field in such a way 
as to include the maximum number of microvessels. The 
highest value obtained among the three fields was reported 
as HMC.World Journal of Surgical Oncology 2005, 3:16 http://www.wjso.com/content/3/1/16
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monal therapy (tamoxifen), or some combination of the
aforementioned). Specifically, 6 patients received only
radiotherapy, 7 patients received only hormonal therapy
and 2 patients received only chemotherapy. For combined
therapies, 6 patients received radiotherapy with hormonal
therapy, 3 patients received radiotherapy with chemother-
apy, 4 patients received hormonal therapy with
chemotherapy and 3 patients received all three methods
of adjuvant therapy.
Patient outcome
All cases reviewed in this study came from the records of
the Saskatchewan Cancer Agency between 1975 and
1997. Thirty-three of 47 patients (70%) died in the time
period considered. Of the remaining 14 patients (30%), 9
(64%) had been followed for 10 years or more and 5
(36%) patients had been followed for under 10 years. Sev-
enteen patients (36%) had documented relapse. The aver-
age age at death for patients with relapse was 72 years
while the average age at death for relapse-free patients was
78 years. Although 70% of patients did die in this study,
thirty-two patients (68%) survived at least 5-years after
the diagnosis of breast cancer.
The Kaplan-Meier curves relating prognostic variables to
death and relapse are illustrated in figure 5. There were
significantly shorter survival times when the age of
diagnosis was ≥  65 years (p < 0.001) and when tumor size
was larger (p < 0.01). However, there were no significant
differences in the times to relapse by any of the clinical
variables. In addition to this, there were no significant dif-
ferences in survival times or times to relapse for any of the
MVD markers when categorized by the median score
(Table 3).
Microvascular density and clinical variables
Regardless of whether MVD was considered as a continu-
ous variable or as a categorical variable, there were no sig-
nificant differences in MVD by demographic (age group)
or clinico-pathological features (tumour size or node sta-
tus) although some of the differences may be clinically
important. Table 4 provides median values of MVD mark-
ers at different levels of clinico-pathological variables.
Microvascular density within individual markers
Measures of MVD (AMC, CMC and HMC) were compared
within each marker. These correlations are illustrated in
figure 6.
CD31
Significant correlations (p < 0.01) were observed between
all methods of measure (AMC correlates with CMC, CMC
correlates with HMC, and HMC correlates with AMC) for
CD31. The correlations between AMC and CMC, and
AMC and HMC were moderate-strong (ρ  = 0.76 and ρ  =
Frequency of male breast cancer cases by age Figure 4
Frequency of male breast cancer cases by age. This illus-
trates the age distribution of male breast cancer patients in 
this study. This is expressed as a percentage of the total 
number of patients. Note the predilection for older men.
Table 2: Clinico-pathological characteristics and survival of the 
study population. The adjacent table is a summary of clinico-
pathological data of interest in this study.
Characteristics No. of cases %
Number of patients 47 100
Tumor size, T
T1 (≤  2 cm) 20 43
T2 (>2 cm, ≤  5 cm) 22 47
T3 (>5 cm) 5 11
Node status
N(-) 26 55
N(+) 21 45
Overall survival, years
<10 27 64
≥  10 15 36
Total evaluated 42 100
Relapse-free survival, years
<10 29 69
≥  10 13 31
Total evaluated 42 100World Journal of Surgical Oncology 2005, 3:16 http://www.wjso.com/content/3/1/16
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Kaplan Meier curves for clinical variables with time to death (left column) and time to relapse (right column) Figure 5
Kaplan Meier curves for clinical variables with time to death (left column) and time to relapse (right column). This fig-
ure illustrates the percentage of patients with relapse-free survival across clinical groupings of age, node status and tumor size.
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0.60 respectively); the correlation between CMC and
HMC was strong (ρ  = 0.88).
CD34
Significant correlations (p < 0.01) were observed between
all methods of measure (AMC correlates with CMC, CMC
correlates with HMC, and HMC correlates with AMC) for
CD34. All correlations were moderately-weak or moder-
ate-strong (ρ  = 0.45 for AMC and CMC, ρ  = 0.41 for AMC
and HMC, and ρ  = 0.77 for CMC and HMC).
CD105
Significant correlations (p < 0.01) were observed between
all methods of measure (AMC correlates with CMC, CMC
correlates with HMC, and HMC correlates with AMC) for
CD105. The correlations between AMC and CMC, and
AMC and HMC were moderate-strong and moderate-
weak (ρ  = 0.62 and ρ  = 0.49 respectively); the correlation
between CMC and HMC was strong (ρ  = 0.82).
VWF
A significant correlation (p < 0.01) was observed between
CMC and HMC for VWF. A trend correlation (p < 0.10)
was observed between AMC and HMC. Correlations were
moderate-weak and weak (ρ  = 0.47 and ρ  = 0.25 respec-
tively). There was no significant relationship between
AMC and CMC for this marker.
VEGF
Significant correlations (p < 0.01) were observed between
AMC and CMC, and between CMC and HMC for VEGF.
Correlations were moderate-weak and moderate-strong (ρ
= 0.43 and ρ  = 0.68 respectively). There was no significant
relationship between AMC and HMC for this marker.
Discussion
The markers
VEGF also called vascular permeability factor (VPF) is an
important angiogenic activator, for both physiological
and pathological angiogenesis [29,30], and it may be
associated with inflammation. VEGF plays an essential
role in embryonic vasculogenesis and angiogenesis
[31,32]. It has also been implicated in postnatal develop-
ment of the glomerulus [33,34] and endochondral bone
[35,36].
VEGF mRNA has been shown to be up-regulated in the
majority of human tumors investigated [37], and carci-
noma of the human breast is one of these. [38,39]. In
addition, VEGF has been implicated in psoriasis [40],
brain edema [41], polycystic ovary syndrome [29], age-
related macular degeneration (AMD) and other
intraocular neovascular syndromes [42-44] The expres-
sion of VEGF is triggered by hypoxia. That is to say, low
oxygen tension provokes VEGF mRNA expression [45].
Table 3: Results from log rank test based on Kaplan Meier curves for microvascular density variables categorized at their median. The 
adjacent table reports the test statistic and p-value from the log rank test comparing differences in survival time and time to relapse 
between different levels of clinico-pathological variables.
Death Relapse
Log rank test statistic p-value Log rank test statistic p-value
VWF
AMC 0.04 0.83 0.46 0.50
CMC 0.70 0.40 0.02 0.88
HMC 0.01 0.93 0.45 0.50
CD31
AMC 1.79 0.18 0.05 0.83
CMC 0.36 0.55 0.00 0.98
HMC 0.15 0.70 0.60 0.44
CD34
AMC 0.19 0.67 0.91 0.34
CMC 0.19 0.66 0.37 0.54
HMC 0.08 0.78 0.30 0.59
CD105
AMC 0.59 0.44 0.01 0.93
CMC 0.10 0.75 0.70 0.40
HMC 0.23 0.63 0.06 0.80
VEGF
AMC 0.21 0.65 0.32 0.57
CMC 1.70 0.19 0.44 0.51
HMC 0.47 0.49 0.25 0.61World Journal of Surgical Oncology 2005, 3:16 http://www.wjso.com/content/3/1/16
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An excellent review of CD105 and its involvement in ang-
iogenesis has been written by Duff et al., [46]. CD105
(endoglin) is commonly expressed by angiogenic
endothelial cells [46-48]. CD105 is an important pro-ang-
iogenic factor. Transforming growth factor β  exerts an
inhibitory influence on cell proliferation, migration and
microvessel formation. The suppressive effect of CD105
on transforming growth factor β , thus, contributes to ang-
iogenesis [49]. It is, therefore, no surprise to observe ele-
vated CD105 expression in various tumor endothelia [50-
52], including breast cancer [53]. CD105 may be shed
into the blood stream. The measure of serum endoglin
appears to provide important prognostic information in
cancer patients [54,55].
CD31 is an important part of the endothelial intercellular
junction [56] and it plays a crucial role in leukocyte migra-
tion through vascular endothelial intracellular junctions
[57-59]. This molecule is at least partially responsible for
the adhesion between leucocytes/endothelial cells, leuco-
cytes/platelets, and endothelial cells/endothelial cells
[57,60-65]. This adhesion is likely the result of CD31-
CD31 [66] interactions (homophilic interactions)
although adhesion between CD31 and other components
of the cell membrane has been demonstrated (heter-
ophilic interactions) [61,67-70].
CD31 also exhibits signal transduction; its dimerization
appears to upregulate integrin function [71]. This mole-
cule appears to be involved in thrombosis, angiogenesis,
wound healing, and inflammation [61]. CD31 is known
Table 4: Microvascular density levels at various levels of clinico-pathological variables. The adjacent table reports median MVD levels 
at different levels of clinico-pathological variables. None of the comparisons are statistically significant
Age group Tumor size Node status
<65 years <65 years T1 T2 T3 Negative Positive
VWF
AM
C
15.6 (5.7) 15.0 (5.8) 15.8 (5.5) 13.5 (5.3) 17.5 (27.9) 14.2 (5.2) 15.6 (5.2)
CM
C
53.7 (24.7) 47.2 (50.2) 44.8 (30.5) 50.3 (43.7) 67.5 (40.3) 48.5 (39.8) 50.0 (35.6)
HM
C
84.0 (50.3) 70.0 (48.5) 86.5 (48.6) 69.0 (58.5) 70.0 (41.8) 84.0 (53.5) 69.3 (44.0)
CD31
AM
C
5.9 (20.9) 14.5 (28.8) 6.8 (28.6) 11.4 (30.5) 15.4 (61.7) 7.2 (17.9) 10.4 (32.6)
CM
C
18.8 (41.4) 26.2 (28.6) 15.7 (38.0) 29.3 (28.9) 20.7 (81.0) 17.9 (33.7) 32.5 (36.5)
HM
C
36.5 (44.8) 38.0 (27.0) 28.0 (40.0) 43.6 (22.3) 30.0 (107.4) 35.9 (40.0) 43.0 (42.6)
CD34
AM
C
19.7 (9.6) 19.8 (10.5) 21.0 (9.0) 17.3 (11.5) 20.0 (81.8) 18.8 (8.3) 19.9 (11.4)
CM
C
52.0 (21.8) 41.3 (35.0) 43.3 (29.4) 52.0 (34.2) 48.5 (46.5) 47.2 (35.0) 50.7 (29.0)
HM
C
89.0 (50.5) 70.0 (77.0) 79.0 (54.3) 86.0 (83.1) 88.0 (79.2) 90.0 (63.3) 70.0 (60.9)
CD10
5
AM
C
2.7 (4.4) 4.4 (4.3) 2.7 (3.8) 4.4 (5.4) 5.4 (10.0) 3.0 (4.7) 4.0 (3.6)
CM
C
8.8 (14.3) 10.7 (13.2) 7.0 (13.8) 10.9 (14.9) 14.3 (31.7) 9.2 (14.5) 10.2 (10.6)
HM
C
29.0 (24.5) 32.0 (34.5) 28.5 (30.3) 30.5 (49.3) 39.0 (156.0) 26.5 (33.0) 31.0 (20.0)
VEGF
AM
C
7.5 (20.0) 17.9 (25.1) 11.9 (25.5) 15.4 (26.8) 5.8 (64.9) 13.4 (21.8) 13.2 (29.2)
CM
C
42.5 (47.0) 39.4 (33.6) 47.5 (72.9) 40.8 (39.5) 36.3 (45.6) 41.1 (45.1) 42.3 (58.8)
HM
C
58.8 (103.1) 80.0 (87.6) 70.3 (113.6) 66.0 (79.1) 80.0 (55.9) 69.8 (86.2) 79.0 (92.8)
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Microvascular density correlations within each marker Figure 6
Microvascular density correlations within each marker. This figure illustrates all the relationships between the different 
methods of MVD measurement for each marker.
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to be a co-signal transducer for macrophages, inducing
respiratory burst.
CD34 is a glycosylated type I transmembrane protein [72]
which is expressed on hematopoietic stem cells, commit-
ted hematological progenitor cells [73-75], small vessel
endothelial cells [76,77], tumors of epithelial origin
[78,79] and a limited number of other cell populations
including some haematological malignancies [72].
As specific ligands are still undefined, the precise role
CD34 plays in early hematopoiesis remains uncertain. It
is thought that differential splicing of sugar residues on
CD34 may permit it to host a variety of ligands under dif-
ferent conditions [80]. Despite our meager understanding
of this complex molecule there is evidence indicating that
hematopoietic CD34 plays a role in modulating adhesion
(this has been reviewed previously [72]).
Factor VIII related antigen, or von Willebrand factor
(VWF), is a plasma protein produced by endothelial cells
[81,82]. VWF is also present in platelets, as it is produced
by their megakaryocytic precursor [83].
VWF is a multifunctional protein. It is known to mediate
adhesion/aggregation of platelets in clot formation
(reviewed in [84]). In addition to this, VWF acts as a chap-
erone for circulating factor VIII. About 1 – 2% of VWF is
bound by factor VIII [85]. This non-covalent bond pro-
longs the survival of factor VIII in the plasma. When the
coagulation cascade is triggered, thrombin cleaves the
complex, thereby freeing factor VIII to participate coagula-
tion [86] (reviewed in [87]).
Age at diagnosis
Male breast cancer is a disease of older men. The likeli-
hood of this occurring in older men that is illustrated in
this study is not surprising as this is the case for most stud-
ies of e breast cancer in males [88,89]. As mortality from
common conditions (e.g. cardiovascular disease) within
this group improves due to advances in treatment/inter-
vention and a larger proportion of the population enters
this age group, it seems that the relative incidence of male
breast cancer is likely to rise. Such is the finding in a recent
meta-analysis of male breast carcinoma [1].
Survival
In this study, 70% of the reviewed patients died. Though
this number may seem high, only half of those who died
had documented relapse prior to the time of death. There
is, however, an interesting difference between average age
at death for relapsed and relapse-free patients, 72 years
versus 78 years respectively. It appears that male breast
cancer is contributing to mortality, but this study did not
examine the effects of co-morbid conditions. The
expected life remaining for a 65 year old male in Saskatch-
ewan between 1995 and 1997 was 16.7 years (expected
age approximately 82 years) [90].
Increased tumor size increases the likelihood of death for
male breast cancer patients in this study (figure 5). One
possible explanation for this relationship is as follows: a
tumor's size may be a function of its rate of growth and
time of growth; these characteristics seem likely to
increase the opportunity for relapse and metastasis. Thus,
we might expect large tumors to relapse more frequently
than small ones, and therefore, also contribute to death.
It appears that younger patients had a significantly better
chance of not experiencing death (figures 5). This phe-
nomenon is possibly related to improved response to
treatment in younger patients; alternatively, this relation-
ship may be demonstrating that younger patients are diag-
nosed with less advanced disease and vice versa. Evidence
supports advanced age [88,89] and tumor size [91] as
important negative prognostic factors.
This study was not able to clearly demonstrate statistically
significant differences in survival for node status. In the
available literature axillary node status is an important
prognostic factor [91-94].
Microvascular density, though it was the primary focus of
this study, did not demonstrate statistically significant
association with survival, demographic or clinico-patho-
logical features. However, we cannot discount the impor-
tance of angiogenesis in tumor progression. The lack of
correlation in this study may have been influenced by the
lack of statistical power, the methods used, the age of the
tissue, advanced stage of disease at presentation and
method of analysis.
In most tumors studied, MVD has been identified as a
prognostic factor and has had important correlations to
clinical variables [12-16]. In most studies where angio-
genesis has been evaluated in cancer of the female breast,
MVD is an important prognostic factor [19-22]. In one
study of male breast cancer using CD34 to highlight ves-
sels, it was concluded that MVD was an important prog-
nostic tool [26].
In an angiogenesis methodology study of 109 women
with breast cancer by Kato et al., [18] it was found that
CMC and HMC did not correlate to clinico-pathological
variables other than peritumor vascular invasion. AMC
was found to have prognostic value. The methods used to
report microvessel density were modeled after this work
by Kato et al, [18].World Journal of Surgical Oncology 2005, 3:16 http://www.wjso.com/content/3/1/16
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Despite a lack of strong evidence, in our study, to support
angiogenesis as an independent prognostic factor, there is
no evidence to disprove angiogenesis plays a critical role
in tumor development. As angiogenesis remains a likely
step in tumor progression, we must continue to recognize
this process as a potential target for anti-tumor therapy.
Microvascular density within each marker
There were some important correlations between the dif-
ferent methods of measure for MVD (AMC, CMC and
HMC) within the various markers. CD31, CD34 and
CD105 were the strongest in this regard with correlations
that were very significant (p < 0.01) and correlations that
were usually moderate to strong. The correlations within
VWF and VEGF were not all significant, and the relation-
ship was moderate to weak.
It could also be that VWF and VEGF are differentially
expressed in male breast cancer tissue. This seems to be
the case for VEGF. In fact, it was observed that VEGF had
a propensity to be over-expressed in regions where there
were invading lymphocytes. This may produce a patchy
pattern of expression, which could have an important
effect on microvessel counts.
For the most part, this study saw strong correlations
between the various microvessel count methods within
the markers. Critics may suggest that evaluation of micro-
vascular density for prognosis in tumors is flawed
because, within a tumor, microvascular density is hetero-
geneous [24,95]. However, the correlations observed in
this study support the notion that tumor vasculature is
predictable (but not ubiquitous or necessarily
homogeneous) from the centre, periphery and vascular
hotspot of a tumor. Notably, similar research in female
invasive ductal carcinoma of the breast using VWF MVD
assessment techniques also demonstrated correlation
between central, peripheral and highest microvessel den-
sities [18].
Microvessel determination, by the methods used in this
study, is dependant on a predictable pattern of vasculature
within a tumor. Such predictability allows for practical (in
terms of time, money and ease of use) application of
important clinical prognostic features of the markers. Fur-
ther research to examine the relationship between these
markers in cancer is wanting. Such information may prove
important in improving the prognostic value of MVD
determination.
Conclusion
From this evaluation of angiogenesis in male breast can-
cer, we can draw the following conclusions:
Microvascular density does not appear to be an independ-
ent prognostic factor in male breast cancer. Tumor vascu-
lature (as measured by microvessel determination using
antibodies to endothelial markers such as CD31, CD34,
CD105) is strongly related throughout a tumor section (p
< 0.01). Other endothelial markers such as VWF and
VEGF appear to have a moderate to weak relationship.
Advanced age at diagnosis and increased tumor size
increases the likelihood of death for men with breast
cancer.
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